M&T Bank Corp Kiniksa Pharmaceuticals, Ltd. Transaction History

M&T Bank Corp

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 07, 2024	SELL	$17.63 - $21.74 $1,375 - $1,695	-78 Reduced 0.21%	36,334 $716,000
Q4 2023 Feb 06, 2024	SELL	$14.37 - $19.07 $8,636 - $11,461	-601 Reduced 1.62%	36,412 $638,000
Q3 2023 Nov 02, 2023	SELL	$13.62 - $20.2 $275,873 - $409,151	-20,255 Reduced 35.37%	37,013 $642,000
Q2 2023 Aug 09, 2023	BUY	$10.44 - $16.48 $138,914 - $219,282	13,306 Added 30.27%	57,268 $806,000
Q1 2023 May 11, 2023	BUY	$10.7 - $15.79 $152,988 - $225,765	14,298 Added 48.2%	43,962 $473,000
Q4 2022 Feb 13, 2023	BUY	$11.42 - $17.05 $169,301 - $252,766	14,825 Added 99.91%	29,664 $444,000
Q4 2022 Feb 13, 2023	SELL	$11.42 - $17.05 $269,523 - $402,397	-23,601 Reduced 61.4%	14,839 $222,000
Q3 2022 Nov 14, 2022	SELL	$9.76 - $13.41 $86,434 - $118,758	-8,856 Reduced 18.72%	38,440 $494,000
Q1 2022 May 09, 2022	BUY	$9.3 - $12.37 $238,191 - $316,820	25,612 Added 118.11%	47,296 $470,000
Q4 2021 Feb 07, 2022	BUY	$10.39 - $15.15 $12,291 - $17,922	1,183 Added 5.77%	21,684 $255,000
Q3 2021 Oct 28, 2021	BUY	$11.39 - $16.23 $109,469 - $155,986	9,611 Added 88.26%	20,501 $234,000
Q1 2021 May 06, 2021	BUY	$16.68 - $23.97 $181,645 - $261,033	10,890 New	10,890 $202,000
Q1 2020 May 14, 2020	SELL	$11.0 - $19.76 $179,289 - $322,068	-16,299 Closed	0 $0
Q4 2019 Feb 07, 2020	BUY	$5.24 - $12.96 $14,713 - $36,391	2,808 Added 20.81%	16,299 $180,000
Q3 2019 Nov 12, 2019	BUY	$8.15 - $15.88 $25,199 - $49,100	3,092 Added 29.73%	13,491 $115,000
Q2 2019 Aug 12, 2019	BUY	$13.2 - $20.39 $137,266 - $212,035	10,399 New	10,399 $141,000

1.95M

Ticker KNSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,470,400
Market Cap $751M
Description
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...

Get notified when there are updates to the investment portfolio of M&T Bank Corp, based on Form 13F filings with the SEC.

Stay updated on M&T Bank Corp with notifications on news.